Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulationJ Kienast, Steven M. Opal, Mathias Juers et al.|Journal of Thrombosis and Haemostasis|2005Cited by 434
High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: Efficacy and safety*Christian J. Wiedermann, Steven M. Opal, Johannes Hoffmann et al.|Critical Care Medicine|2006Cited by 188
Pathophysiologic Correlates of Thromboembolism in Nonvalvular Atrial Fibrillation: II. Dense Spontaneous Echocardiographic Contrast (The Stroke Prevention in Atrial Fibrillation [SPAF-III] Study)Richard Asinger, Jonathan L. Halperin, Robert M. Rothbart et al.|Journal of the American Society of Echocardiography|1999Cited by 120
Benefit/risk profile of high-dose antithrombin in patients with severe sepsis treated with and without concomitant heparinJohannes Hoffmann, Richard Strauß, Brian Warren et al.|Thrombosis and Haemostasis|2006Cited by 85
Warfarin safety and efficacy in patients with thoracic aortic plaque and atrial fibrillationJoseph L. Blackshear, Lesly A. Pearce, Miguel Zabalgoitia et al.|The American Journal of Cardiology|1999Cited by 65